Could a shorter steroid course be just as good for HIV-Related pneumonia?

NCT ID NCT03856229

ENROLLING_BY_INVITATION Disease control Sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a shortened steroid regimen (8 days for moderate, 14 days for severe pneumonia) against the standard 21-day course in 196 HIV patients with Pneumocystis pneumonia. The goal is to see if the shorter treatment is non-inferior in preventing death and complications. Participants must be on standard antibiotics and start steroids within 48 hours of admission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: prednisolone (or methylprednisolone equivalent)
What this could lead to: If successful, this could show that a shorter steroid course is just as effective, reducing side effects and simplifying treatment for HIV patients with this type of pneumonia.
What could go wrong: This is a non-inferiority trial, so it may only confirm that the shorter course is not worse, not necessarily better. The results may not apply to patients with other health conditions or those not on standard antibiotics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS pneumocystosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV/AIDS PNEUMOCYSTIS STEROID

Contacts and locations

Locations

Centro de Investigacion en Enfermedades Infecciosas

México, State of Mexico, 14080, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.